Skip to main content
SpringerLink
Log in

PKM2 and ACVR 1C are prognostic markers for poor prognosis of gallbladder cancer

  • Research Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

An Erratum to this article was published on 26 October 2013

Abstract

Purpose

To identify biological markers related to the progression and prognosis of GBC.

Methods

The expressions of pyruvate kinase isoenzyme type M2 (PKM2) and activin A receptor type IC (ACVR 1C) in 46 squamous cell/adenosquamous carcinomas (SC/ASC) and 80 adenocarcinomas (AC) were examined using immunohistochemistry.

Results

Positive PKM2 and negative ACVR 1C expressions were significantly associated with lymph node metastasis, invasion and TNM stage of SC/ASCs and ACs. Univariate Kaplan–Meier analysis showed that either elevated PKM2 or loss of ACVR 1C expression significantly correlated with shorter average survival times in both SC/ASC and AC patients. Multivariate Cox regression analysis showed that positive PKM2 expression and loss of ACVR 1C expression were poor prognosis biomarkers in both SC/ASC and AC patients.

Conclusions

Our study suggested that PKM2 overexpression is a marker of metastasis, invasion and poor prognosis of GBC. ACVR 1C is a tumor suppressor, and lowered ACVR 1C expression is an important marker for the metastasis, invasion, and prognosis of GBC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Jayaraman S, Jarnagin WR. Management of gallbladder cancer. Gastroenterol Clin North Am. 2010;39:331–42.

    Article  PubMed  Google Scholar 

  2. Hawkins WG, DeMatteo RP, Jarnagin WR, Ben-Porat L, Blumgart LH, Fong Y. Jaundice predicts advanced disease and early mortality in patients with gallbladder cancer. Ann Surg Oncol. 2004;11:310–5.

    Article  PubMed  Google Scholar 

  3. de Aretxabala X, Roa I, Burgos L, Losada H, Roa JC, Mora J, et al. Gallbladder cancer: an analysis of a series of 139 patients with restricted to the subserosal layer. J Gastrointest Surg. 2006;10:186–92.

    Article  PubMed  Google Scholar 

  4. Ootani T, Shirai Y, Tsukada K, Muto T. Relationship between gallbladder carcinoma and the segmental type of adenomyomatosis of the gallbladder. Cancer. 1992;69:2647–52.

    Article  CAS  PubMed  Google Scholar 

  5. Roa JC, Tapia O, Cakir A, Basturk O, Dursun N, Akdemir D, et al. Squamous cell and adenosquamous carcinomas of the gallbladder: clinicopathological analysis of 34 cases identified in 606 carcinomas. Mod Pathol. 2011;24:1069–78.

    Article  PubMed  Google Scholar 

  6. Mazurek S. Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. Int J Biochem Cell Biol. 2011;43:969–80.

    Article  CAS  PubMed  Google Scholar 

  7. Mazurek S, Boschek CB, Hugo F, Eigenbrodt E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol. 2005;15:300–8.

    Article  CAS  PubMed  Google Scholar 

  8. Spoden GA, Mazurek S, Morandell D, Bacher N, Ausserlechner MJ, Jansen-Dürr P, et al. Isotype-specific inhibitors of the glycolytic key regulator pyruvate kinase subtype M2 moderately decelerate tumor cell proliferation. Int J Cancer. 2008;123:312–21.

    Article  CAS  PubMed  Google Scholar 

  9. Jiang K, He B, Lai L, Chen Q, Liu Y, Guo Q, et al. Cyclosporine A inhibits breast cancer cell growth by downregulating the expression of pyruvate kinase subtype M2. Int J Mol Med. 2012;30:302–8.

    CAS  PubMed  Google Scholar 

  10. Watanabe R. Activin receptor-like kinase and the insulin gene. Vitam Horm. 2011;85:1–27.

    Article  CAS  PubMed  Google Scholar 

  11. Tsuchida K, Nakatani M, Uezumi A, Murakami T, Cui X. Signal transduction pathway through activin receptors as a therapeutic target of musculoskeletal diseases and cancer. Endocr J. 2008;55:11–21.

    Article  CAS  PubMed  Google Scholar 

  12. Angenete E, Langenskiöld M, Palmgren I, Falk P, Oresland T, Ivarsson ML. Transforming growth factor beta-1 in rectal tumor, mucosa and plasma in relation to radiotherapy and clinical outcome in rectal cancer patients. Int J Colorectal Dis. 2007;22:1331–8.

    Article  PubMed  Google Scholar 

  13. Joshi A, Cao D. TGF-beta signaling, tumor microenvironment and tumor progression: the butterfly effect. Front Biosci. 2010;15:180–94.

    Article  CAS  Google Scholar 

  14. Liu DC, Yang ZL, Jiang S. Identification of PEG10 and TSG101 as carcinogenesis, progression, and poor-prognosis related biomarkers for gallbladder adenocarcinoma. Pathol Oncol Res. 2011;17:859–66.

    Article  CAS  PubMed  Google Scholar 

  15. Kondo M, Dono K, Sakon M, Shimizu J, Nagano H, Nakamori S, et al. Adenosquamous carcinoma of the gallbladder. Hepatogastroenterology. 2002;49:1230–4.

    PubMed  Google Scholar 

  16. Mazurek S. Pyruvate kinase type M2: a key regulator within the tumour metabolome and a tool for metabolic profiling of tumours. Ernst Schering Found Symp Proc. 2007;4:99–124.

    PubMed  Google Scholar 

  17. Hoda MA, Münzker J, Ghanim B, Schelch K, Klikovits T, Laszlo V, et al. Suppression of activin A signals inhibits growth of malignant pleural mesothelioma cells. Br J Cancer. 2012;107:1978–86.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Conflict of interest

All authors declared no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Surgery, Central South University, Changsha, 410011, Hunan, People’s Republic of China

    J. Li

  2. Research Laboratory of Hepatobiliary Diseases, Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, People’s Republic of China

    Z. Yang

  3. Department of Pathology, Third Xiangya Hospital, Central South University, Changsha, 410011, Hunan, People’s Republic of China

    Q. Zou & Y. Yuan

  4. Department of Pathology, Xiangya Medical School, Central South University, Changsha, 410011, Hunan, People’s Republic of China

    J. Li

  5. Department of Hepatobiliary and Pancreatic Surgery, Hunan Provincial People’s Hospital, Changsha, 410007, Hunan, People’s Republic of China

    L. Liang

  6. Department of Pathology, Loudi Central Hospital, Loudi, 417011, Hunan, People’s Republic of China

    G. Zeng

  7. Department of Pathology, Hunan Provincial Tumor Hospital, Changsha, 410013, Hunan, People’s Republic of China

    S. Chen

Authors
  1. J. Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Z. Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Q. Zou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Y. Yuan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. L. Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G. Zeng
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S. Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Z. Yang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Li, J., Yang, Z., Zou, Q. et al. PKM2 and ACVR 1C are prognostic markers for poor prognosis of gallbladder cancer. Clin Transl Oncol 16, 200–207 (2014). https://doi.org/10.1007/s12094-013-1063-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-013-1063-8

Keywords

Search

Navigation